Life Sciences Centre, Vilnius University, 03101, Vilnius, Lithuania.
Laboratory of Cancer Epidemiology, National Cancer Institute, Vilnius, Lithuania.
Tech Coloproctol. 2024 Feb 15;28(1):33. doi: 10.1007/s10151-023-02873-4.
The aim of this study was to examine whether the combination of serum tumor markers (carcinoembryonic antigen [CEA], carbohydrate antigen [CA]72-4, CA19-9) improves sensitivity and accuracy in the diagnosis of colorectal cancer and precancerous lesion tubular adenoma.
An automatic electrochemiluminescence immunoassay with matched kits (ECLIA) was performed on a Roche Cobas e411 analyzer to determine the levels of serum CEA, CA72-4, and CA19-9 in 35 patients with early colorectal cancer, 87 patients with tubular adenoma, and 58 healthy people undergoing colonoscopy after positive fecal immunochemical test (FIT) in a colorectal cancer screening program 2021 January to April. The values of these three tumor markers in the diagnosis of colorectal cancer and tubular adenoma were analyzed.
180 patients (92 female and 88 male) were included into the study. We compared serum CEA, CA72-4 and CA19-9 markers among 3 groups: healthy people (mean age 64,0 ±8,6), patients with tubular adenoma (mean age 62,7 ± 6,4) and colorectal cancer (mean age 59,2 ±6,2). The levels of serum CEA, CA72-4, and CA19-9 were higher in the colorectal cancer group than in the tubular adenoma group and healthy subjects, and these differences were significant (p < 0.05). The combination of CEA, CA72-4, and CA19-9 had a higher diagnostic value for colorectal cancer compared to single markers, and the positive detection rate was 54.3%. The diagnostic power when using all three markers was the best, and applied for colorectal cancer and tubular adenoma.
The combination of CA72-4, CEA, and CA19-9 markers increases the sensitivity and accuracy in the diagnosis of colorectal cancer and can thus be considered an important tool for early colorectal diagnosis.
本研究旨在探讨血清肿瘤标志物（癌胚抗原[CEA]、糖类抗原[CA]72-4、CA19-9）联合检测是否能提高结直肠癌及癌前病变管状腺瘤的诊断敏感性和准确性。
采用罗氏 cobas e411 分析仪配套试剂盒（ECLIA）对 2021 年 1 月至 4 月在结直肠癌筛查项目中经粪便免疫化学试验（FIT）阳性后行结肠镜检查的 35 例早期结直肠癌患者、87 例管状腺瘤患者和 58 例健康对照者的血清 CEA、CA72-4 和 CA19-9 水平进行检测。分析了这三种肿瘤标志物在结直肠癌和管状腺瘤诊断中的应用价值。
本研究共纳入 180 例患者（92 例女性，88 例男性）。我们比较了三组人群的血清 CEA、CA72-4 和 CA19-9 标志物：健康人群（平均年龄 64.0±8.6 岁）、管状腺瘤患者（平均年龄 62.7±6.4 岁）和结直肠癌患者（平均年龄 59.2±6.2 岁）。结直肠癌组患者的血清 CEA、CA72-4 和 CA19-9 水平均高于管状腺瘤组和健康对照组，差异有统计学意义（p<0.05）。CEA、CA72-4 和 CA19-9 联合检测对结直肠癌的诊断价值高于单项检测，阳性检出率为 54.3%。三种标志物联合应用对结直肠癌和管状腺瘤的诊断效能最佳。
CA72-4、CEA 和 CA19-9 标志物联合检测可提高结直肠癌的诊断敏感性和准确性，可作为结直肠癌早期诊断的重要工具。
